• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.

作者信息

Chang Christina Y, Nguyen Christine P, Wesley Barbara, Guo Jia, Johnson Laura Lee, Joffe Hylton V

机构信息

From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

出版信息

N Engl J Med. 2020 Dec 10;383(24):e131. doi: 10.1056/NEJMp2031055. Epub 2020 Nov 3.

DOI:10.1056/NEJMp2031055
PMID:33140923
Abstract
摘要

相似文献

1
Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.撤销Makena的批准——美国食品药品监督管理局药物评价和研究中心的一项提议
N Engl J Med. 2020 Dec 10;383(24):e131. doi: 10.1056/NEJMp2031055. Epub 2020 Nov 3.
2
Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.早产与17-羟孕酮——为何美国食品药品监督管理局不应撤销批准
N Engl J Med. 2020 Dec 10;383(24):e130. doi: 10.1056/NEJMp2031727. Epub 2020 Nov 3.
3
A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.17α-羟孕酮己酸酯预防复发性早产的故事编年史。
Am J Obstet Gynecol. 2021 Feb;224(2):175-186. doi: 10.1016/j.ajog.2020.09.045. Epub 2020 Oct 6.
4
Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.17α-羟孕酮己酸酯的加速审批：一个警示故事。
Obstet Gynecol. 2020 May;135(5):1207-1213. doi: 10.1097/AOG.0000000000003787.
5
FDA Revokes Approval for Preterm Birth Drug Makena.美国食品药品监督管理局撤销早产药物Makena的批准。
JAMA. 2023 May 2;329(17):1444. doi: 10.1001/jama.2023.6257.
6
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?预防早产药物的验证性试验未发现益处，那为何仍在开这种药？
JAMA. 2020 Apr 7;323(13):1229-1232. doi: 10.1001/jama.2020.1486.
7
FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.美国食品和药物管理局批准与药房配制 17-OHPC-减少复发性早产，产科医生需要考虑的当前问题。
Curr Med Res Opin. 2020 Aug;36(8):1393-1401. doi: 10.1080/03007995.2020.1783220. Epub 2020 Jun 30.
8
Defining the clinical response to 17-alpha hydroxyprogesterone caproate.确定己酸17-α-羟孕酮的临床反应。
Am J Obstet Gynecol. 2018 Dec;219(6):623-625. doi: 10.1016/j.ajog.2018.08.040. Epub 2018 Aug 29.
9
Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).美国食品和药物管理局批准 Makena（17α-羟基黄体酮己酸酯）导致的不必要的医疗费用增加。
Obstet Gynecol. 2011 Jun;117(6):1408-1412. doi: 10.1097/AOG.0b013e31821c2d75.
10
Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.羟孕酮己酸酯原料药及注射液的质量考察。
Drug Dev Ind Pharm. 2012 May;38(5):540-9. doi: 10.3109/03639045.2012.662511. Epub 2012 Feb 13.

引用本文的文献

1
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.美国和欧洲近期撤回的3种PARP抑制剂卵巢癌治疗适应症的监管历史：加速批准途径的经验教训
J Pharm Policy Pract. 2024 Jun 4;17(1):2351003. doi: 10.1080/20523211.2024.2351003. eCollection 2024.
2
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.阿杜卡奴单抗、加速审批与机构：为何 FDA 需要结构改革。
J Law Med Ethics. 2023;51(4):900-919. doi: 10.1017/jme.2024.20. Epub 2024 Mar 13.
3
Integrative analysis of noncoding mutations identifies the druggable genome in preterm birth.
非编码突变的综合分析确定了早产的可用药基因组。
Sci Adv. 2024 Jan 19;10(3):eadk1057. doi: 10.1126/sciadv.adk1057.
4
What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.现在怎么办？对己酸17-α羟孕酮预防复发性早产20多年临床及研究经验的批判性评估。
Am J Obstet Gynecol MFM. 2023 Oct;5(10):101108. doi: 10.1016/j.ajogmf.2023.101108. Epub 2023 Jul 30.
5
New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline.预防自发性早产和早产管理的新药：药物研发管道的全景分析。
BMC Pregnancy Childbirth. 2023 Jul 18;23(1):525. doi: 10.1186/s12884-023-05842-9.
6
Rematching on-the-fly: Sequential matched randomization and a case for covariate-adjusted randomization.实时重配：序贯匹配随机化和协变量调整随机化的案例。
Stat Med. 2023 Sep 30;42(22):3981-3995. doi: 10.1002/sim.9843. Epub 2023 Jul 13.
7
Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.2010-2021 年，咨询委员会投票与美国食品和药物管理局处方药决策的关联。
JAMA Health Forum. 2023 Jul 7;4(7):e231718. doi: 10.1001/jamahealthforum.2023.1718.
8
β3 Receptor Signaling in Pregnant Human Myometrium Suggests a Role for β3 Agonists as Tocolytics.β3 受体信号在妊娠人子宫平滑肌中的作用提示 β3 激动剂作为保胎药的作用。
Biomolecules. 2023 Jun 17;13(6):1005. doi: 10.3390/biom13061005.
9
Ameliorating adverse perinatal outcomes with Lactoferrin: An intriguing chemotherapeutic intervention.用乳铁蛋白改善不良围产期结局：一种有趣的化疗干预措施。
Bioorg Med Chem. 2022 Nov 15;74:117037. doi: 10.1016/j.bmc.2022.117037. Epub 2022 Sep 29.
10
Preterm Birth Therapies to Target Inflammation.针对炎症的早产治疗方法。
J Clin Pharmacol. 2022 Sep;62 Suppl 1(Suppl 1):S79-S93. doi: 10.1002/jcph.2107.